Method development and validations: characterization of critical elements in the development of pharmaceuticals

R. Putheti, R. N. Okigbo, S. Patil, -. MadhusoodansaiAd, vanapu, R. Leburu
{"title":"Method development and validations: characterization of critical elements in the development of pharmaceuticals","authors":"R. Putheti, R. N. Okigbo, S. Patil, -. MadhusoodansaiAd, vanapu, R. Leburu","doi":"10.4314/IJHR.V1I1.55342","DOIUrl":null,"url":null,"abstract":"This review discusses the conceptual aspects of method \nvalidation, its management, processes and schemes and \nhighlights method validation key performance characteristics. Although a thorough validation cannot rule out all potential problems, the process of method development and validation should address the most common ones. Examples of typical problems that can be minimized or avoided are synthesis impurities that co-elute with the analyte peak in an HPLC assay; a particular type of column that no longer produces the separation needed because the supplier of the column has changed the manufacturing process; an assay method that is transferred to a second laboratory \nwhere they are unable to achieve the same detection \nlimit; and a quality assurance audit of a validation report \nthat finds no documentation on how the method was performed during the validation. Problems increase as additional people, laboratories, and equipment are used to perform the method. When the method is used in the developer's laboratory, a small adjustment can usually be made to make the method work, but the flexibility to change it is lost once the method is transferred to other laboratories or used for official product testing. This is especially true in the pharmaceutical industry, where methods are submitted to regulatory agencies and changes may require formal approval before they can be implemented for official testing. The best way to minimize method problems is to perform adequate validation experiments during development. \n \nKeywords: Method validation, method development, pharmaceutical analysis","PeriodicalId":93450,"journal":{"name":"International journal of health research and innovation","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2010-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of health research and innovation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/IJHR.V1I1.55342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14

Abstract

This review discusses the conceptual aspects of method validation, its management, processes and schemes and highlights method validation key performance characteristics. Although a thorough validation cannot rule out all potential problems, the process of method development and validation should address the most common ones. Examples of typical problems that can be minimized or avoided are synthesis impurities that co-elute with the analyte peak in an HPLC assay; a particular type of column that no longer produces the separation needed because the supplier of the column has changed the manufacturing process; an assay method that is transferred to a second laboratory where they are unable to achieve the same detection limit; and a quality assurance audit of a validation report that finds no documentation on how the method was performed during the validation. Problems increase as additional people, laboratories, and equipment are used to perform the method. When the method is used in the developer's laboratory, a small adjustment can usually be made to make the method work, but the flexibility to change it is lost once the method is transferred to other laboratories or used for official product testing. This is especially true in the pharmaceutical industry, where methods are submitted to regulatory agencies and changes may require formal approval before they can be implemented for official testing. The best way to minimize method problems is to perform adequate validation experiments during development. Keywords: Method validation, method development, pharmaceutical analysis
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
方法开发和验证:药物开发中关键元素的表征
本文讨论了方法验证的概念、管理、过程和方案,并强调了方法验证的关键性能特征。尽管彻底的验证不能排除所有潜在的问题,但是方法开发和验证的过程应该解决最常见的问题。可以最小化或避免的典型问题的例子是在HPLC分析中与分析物峰共洗脱的合成杂质;由于色谱柱的供应商改变了制造工艺而不再产生所需分离的特定类型的色谱柱;转移到无法达到相同检测限的第二实验室的分析方法;验证报告的质量保证审计没有发现在验证期间如何执行方法的文档。由于使用了更多的人员、实验室和设备来执行该方法,问题也随之增加。当该方法在开发人员的实验室使用时,通常可以进行小的调整以使该方法工作,但一旦该方法转移到其他实验室或用于正式的产品测试,则失去了更改它的灵活性。在制药行业尤其如此,方法提交给监管机构,更改可能需要正式批准,然后才能实施正式测试。最小化方法问题的最佳方法是在开发期间执行充分的验证实验。关键词:方法验证,方法开发,药物分析
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Knowledge and Attitude of Meningitis Belt Country Passengers Arriving at King Abdul-Aziz International Airport – Jeddah, Saudi Arabia toward Ciprofloxacin as a Meningococcal Disease Prophylaxis The Use of Liposomal Bupivacaine Intraoperatively Through a Superficial Cervical Plexus Blockade for Postoperative Pain Management for Carotid Endarterectomy: a Case Report Innovation in Healthcare Organizations: Concepts and Challenges to Consider Predictive models of health expenditure via regularization: Do low and upper middle income economies share common predictors? Public Health Implication of Mycotoxin Contaminated Pawpaw (Carica papaya L) on Sale in Nigerian Markets
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1